Chordate Medical Holding AB (OSTO:CMH) Change In Receivables : kr0.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Change In Receivables?

Chordate Medical Holding AB's change in receivables for the quarter that ended in Dec. 2023 was kr-0.80 Mil. It means Chordate Medical Holding AB's Accounts Receivable increased by kr0.80 Mil from Sep. 2023 to Dec. 2023 .

Chordate Medical Holding AB's change in receivables for the fiscal year that ended in Dec. 2023 was kr0.57 Mil. It means Chordate Medical Holding AB's Accounts Receivable declined by kr0.57 Mil from Dec. 2022 to Dec. 2023 .

Chordate Medical Holding AB's Accounts Receivable for the quarter that ended in Dec. 2023 was kr0.21 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Chordate Medical Holding AB's Days Sales Outstanding for the three months ended in Dec. 2023 was 39.95.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Chordate Medical Holding AB's liquidation value for the three months ended in Dec. 2023 was kr2.63 Mil.

Chordate Medical Holding AB Change In Receivables Historical Data

The historical data trend for Chordate Medical Holding AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Change In Receivables Chart

Chordate Medical Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.83

-0.82

0.80

-1.75

0.57

Chordate Medical Holding AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-1.42	0.37	0.64	0.36	-0.80

Chordate Medical Holding AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.57 Mil.

Chordate Medical Holding AB (OSTO:CMH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Chordate Medical Holding AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.211	/	0.482	*	91
=	39.95

2. In Ben Graham's calculation of liquidation value, Chordate Medical Holding AB's accounts receivable are only considered to be worth 75% of book value:

Chordate Medical Holding AB's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.455	-	6.869	+	0.75 * 0.211	+	0.5 * 1.771
=	2.63

Chordate Medical Holding AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordate Medical Holding AB (OSTO:CMH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

K1Z:Germany

Address

c/o Regus, Kistagangen 20B, Kista, SWE, 164 40

Website

https://www.chordate.com

Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines